In our murine CKD model, FC treatment decreased serum phosphate by 48% and increased serum iron by 59%, changes that likely contributed to the substantial order-of-magnitude reduction in circulating FGF23 concentrations. This evidence concerns the gene FGF23 and chronic kidney disease.